DFT2 cells express comparable levels of STAT3 to DFT1, which do not change upon treatment with IFNγ in either cell line, and lower levels of Interleukin 1 Receptor, Type 1 (IL1R1), which is upregulated by both tumours in response to IFNγ. This evidence concerns the gene STAT3 and neoplasm.